HDT BIO CORP — Department of Health and Human Services SBIR Phase I: NIAID
HDT BIO CORP — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $599,629
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- NAICS
- —
- Place of performance
- WA
- Period
- —
Description
SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have developed two proprietary adjuvant technologies to enhance humoral and cellular immunityWe will incorporate these to produce a combination adjuvant optimized to augment the immunity and efficacy of an Hinfluenza immunogenThe target adjuvant profile includes promotion of a broader responseaugmentation of durable immunityandprotective efficacy against H Navian influenza